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Abstract
Background: To study the set-up errors, PTV margin and toxicity of cone beam CT (CBCT) guided
hypofractionated radiotherapy with active breathing control (ABC) for patients with non-small cell lung cancer
(NSCLC) or metastatic tumors in lung.
Methods: 32 tumors in 20 patients were treated. Based on the location of tumor, dose per fraction given to tumor
was divided into three groups: 12 Gy, 8 Gy and 6 Gy. ABC is applied for every patient. During each treatment,
patients receive CBCT scan for online set-up correction. The pre- and post-correction setup errors between
fractions, the interfractional and intrafractional, set-up errors, PTV margin as well as toxicity are analyzed.
Results: The pre-correction systematic and random errors in the left-right (LR), superior-inferior (SI), anterior-
posterior (AP) directions were 3.7 mm and 5.3 mm, 3.1 mm and 2.1 mm, 3.7 mm and 2.8 mm, respectively, while
the post-correction residual errors were 0.6 mm and 0.8 mm, 0.8 mm and 0.8 mm, 1.2 mm and 1.3 mm,
respectively. There was an obvious intrafractional shift of tumor position. The pre-correction PTV margin was 9.5
mm in LR, 14.1 mm in SI and 8.2 mm in AP direction. After CBCT guided online correction, the PTV margin was
markedly reduced in all three directions. The post-correction margins ranged 1.5 to 2.1 mm. The treatment was
well tolerated by patients, of whom there were 4 (20%) grade1-2 acute pneumonitis, 3 (15%) grade1 acute
esophagitis, 2 (10%) grade1 late pneumonitis and 1 (5%) grade 1 late esophagitis.
Conclusion: The positioning errors for lung SBRT using ABC were significant. Online correction with CBCT image
guidance should be applied to reduce setup errors and PTV margin, which may reduce radiotherapy toxicity of
tissues when ABC was used.
Background
Radiotherapy is the alternative treatment for patients
with medically inoperable primary non-small-cell lung
cancer (NSCLC) [1], and also for patients with slow
growing metastatic lung tumors [2] which when mana-
ged with high dose localized radiotherapy can prolong
patients’ symptom-free status.
However, even for inoperable stage I non-small cell
lung cancer, the local control rates using standard frac-
tionation schemes (30-76 Gy in 1.8 to 2.0 Gy fractions)
have been reported ranging 45-89% [3-5]. Five year
actuarial survival of conventional radiotherapy ranged
from 6% to 27% [6-9], which was unsatisfactory com-
pared with surgery (with a 5-year survival rate of 60% to
80%) [10]. Dose escalation has been an important issue
to improve local tumor control and overall survival
[11,12]. However, dose escalation by conventional frac-
tionated radiotherapy has the risk of increasing normal
tissue toxicity and prolonging overall treatment time
which will encounter the acceleration of tumor cell
proliferation.
The dose escalation within a short treatment time and
sparing functional lung tissue is potentially addressed by
hypofractionated radiotherapy. It has been shown that
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achieve excellent local control rates as high as 85-95%,
with surprisingly minimal acute or late toxicity [13-15].
The hypofractionation radiotherapy technique employs
multiple radiation beams to target a tumor with extreme
precision, delivering a high dose of radiation, even in a
single fraction. Tumors in the thorax regions are subject
to setup errors and respiration motion, which can result
in inaccurate assessment of organ shape and locations.
Conventionally, these uncertainties are accounted for in
treatment planning by using large margins based on
motion value [16], which can limit dose delivered to
tumor.
Special immobilization and verification devices have
been developed to reduce setup uncertainties. The use
of cone-beam CT (CBCT) has provided 3-dimension
information of patient position which could be utilized
to guide high precision radiotherapy of the lung tumor.
The technique of active breathing control (ABC) has
been used to reduce the breathing motion. The use of
ABC has been reported to have advantages in protection
of lung tissues by reducing respiration motion and lung
density [17]. However, little has been reported on the
combined use of ABC and CBCT in hypofractionated
RT of lung tumor.
Given the availability of onboard cone-beam CT
(CBCT) imaging and ABC at our institution, we set out
to determine how much using image-guided radiotherapy
(IGRT) might affect lung tumor targeting accuracy, target
volume margin requirements, and normal tissue doses.
Methods
Study population and Characterization
Eligibility
Patients with histologically or cytologically confirmed
diagnosis of metastatic malignant tumors within the lung
or primary NSCLC were eligible for treatment. Patients
must have measurable disease and the maximum dia-
meter of tumors is bellow 5 cm. A maximum of 3 lung
tumor targets in one patient were allowable. Patients
with primary NSCLC either had medically inoperable dis-
ease or refused surgery. Patients with metastatic tumors
and with life expectancy ≥ 6 months were treated.
Patients with a history of prior chest radiotherapy were
ineligible. Pretreatment pulmonary function testing was
performed, with FEV1 (minimum forced expiration
volume at 1 second) ≥ 2.0 L and FEV1/FVC (vital capa-
city) ≥ 80%. Patients were required to have an ECOG
performance status of 2 or less, and not on chemotherapy
or hormonal therapy. Informed consent was obtained
from all patients before the treatment was initiated.
Patient characteristics are shown in Table 1
Between April 2006 and August 2007, 20 patients with
inoperable NSCLC or metastatic lung tumors were
treated with IGRT at West China Hospital, Sichuan
University. Patients comprised 12 males and 8 females
aged from 22 to 74 years, with a median age of 54.2
years. Half of the lung tumors were primary NSCLC
and the rests were metastatic which came from the head
and neck (7), esophagus (2) and breast (1). Of the 10
patients with primary NSCLC, 5 were recurrence after
surgical treatment, 3 were ineligible for surgical treat-
ment due to complications and/or advanced age and 2
refused surgery. Ten patients had 1 tumor target, eight
patients had 2 targets and the remaining two patients
had 3 targets. A total of 32 tumor targets were treated
with radiotherapy. The tumor mean size was 23 mm
(ranged 13 - 44 mm) on CT scan.
Immobilization and CT simulation
All patients underwent a virtual radiation simulation
using a stereotactic body frame (SBF) (Elekta Crawley,
UK) for immobilization. A planning CT scan in 3 mm-
cuts of the whole thorax was taken, with the patient in
the treatment position and using the Elekta ABC device
(Elekta, Crawley, UK). To set the threshold of ABC,
the patient was told to take a deep breath and the maxi-
mum inspiration volume was measured. The breath-
h o l dt h r e s h o l dw a ss e ta t3 / 4o ft h em a x i m u m
Table 1 Patient and tumor characteristics
Patient 20
Tumor 32
Age (yrs)
Range 22-74
Median 54.2
≥ 60 yrs 8(40%)
Gender
Male 19 12(60%)
Female 8 (40%)
Resource
Primary 10
Metastatic 10
Histology
Squamous cell carcinoma 5 (25%)
Adenocarcinoma 11(55%)
Unclassified 4 (20%)
Tumor size (mm)
Mean 23
Range 13-40
Tumor location
Right lung 20(63%)
Left lung 12(37%)
Upper lobe 12(37%)
ECOG performance
0 14(70%)
1 6 (30%)
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Page 2 of 9inspiration for each patient. Each patient had accepted
the training course with ABC for 2-5 times before irra-
diation. Oxygen with 5-8 L flow rate was connected to
the inhale pipe to help patients enhance breath holding
time. Patients can release the control switch when he
feels uncomfortable. It is required that the respiration
motion of tumor with ABC should be < 3 mm as
assessed by fluoroscopy before treatment.
Planning and treatment
Treatment planning was performed using the Precise-
PLAN Release 2.1 planning system with considerations
made for pulmonary density inhomogeneity. The full
area integration dose calculation algorithm was used for
dose calculation. Prophylactic nodal irradiation was not
performed. Gross tumor volume (GTV) encompassed 1
mm only the radiologically visible tumor as seen by the
planning CT with the lung window using a window level
of -700 with a width of 1000. Clinical target volume
( C T V )w a sG T Vp l u sa5m mm a r g i ni na l ld i r e c t i o n s .
For the planning target volume (PTV), 5 mm security
margins in all directions were added to the CTV.
Depending on tumor size and location, different frac-
tionation schemes were applied. There were three
groups of different dose per fraction given to the plan-
ning target volume (PTV), prescribed to the 80% iso-
dose. In general, radiotherapy with dose per fraction of
12 Gy prescribed was chosen for small targets and for
targets with peripheral location. In cases of large
tumors, central location and close proximity to critical
structures like large vessels and bronchi: with dose per
fraction of 6 Gy. Other tumors were given radiotherapy
with dose per fraction of 8 Gy. Depend on different sin-
gle dose we chose different numbers of fractions to
make BED (biology effective dose) reach at least 70 Gy.
The primary and metastatic lung tumors were not dif-
ferentially fractionated since in this cohort both primary
and metastatic tumors shared similar histopathological
types with similar radiosensitivity. The patients received
radiotherapy three times per week. The treatment plan-
ning ensured that the esophagus, heart and spinal cord
received the minimum possible dose, but always less
than 50% of the total prescribed tumor dose. According
to linear quadratic equation [E/a =n d×[ 1 + d / ( s/b)],
BED were calculated and shown in Table 2.
CBCT guidance and adjustment
CBCT was used for verification of tumor position
using100 kV, S20 field of view (270 mm), 36.1 mAs,
with the kilovoltage source rotating from 260° and end-
ing at 100° for acquisition of 361 frames [18], which was
done in one breath-hold.
Before each fraction, a first CBCT was acquired recon-
structed and automatically matched to the planning CT.
The positional errors of the target in left-right (LR),
superior-inferior (SI) and anterior-posterior (AP) axis
were calculated with the XVI software. The errors were
corrected online through adjustment of treatment
couch. The second CBCT was acquired after online cor-
rection. If the residual error is less than 2 mm, radio-
therapy was delivered immediately. The third CBCT
were acquired after radiotherapy to estimate the residual
error. The interfractional errors were defined as the off-
set between the pre-correction CBCT and the planning
CT. The intrafraction error was calculated as the differ-
ence between the pre- and post-correction position.
Analysis of positional errors
The inter- and intra-fraction errors are reported as
described [19]: for each patient the mean and standard
deviation (SD) of all setup errors during treatment were
calculated. The group mean error (M) is defined as the
average of all individual means. Σ is defined as the varia-
bility of the means and calculated as the SD of the indi-
vidual means. The random uncertainty s was calculated
as the root-mean-square of the individual SD.
PTV margin reduction and impact on normal tissue dose
As ABC was applied to restrict respiration motion
(<3 mm), to simplify analysis, the internal margin (IM)
due to respiration motion was not included for margin
analysis, only positional uncertainty was accounted for,
according to van Herk [19]: Msetup(PTV margin) = 2.5 Σ +
b√s
2+s
2
p - bsp, where sp = 6.4 mm for lung, b = 0.84 for
SBRT (80% isodose line) [20].
To evaluate the benefit of CBCT-guided online setup
c o r r e c t i o na n dA B Cd e v i c eo nm a r g i nr e d u c t i o nf o r
lung hypofractionated RT, the dose reductions to nor-
mal tissues with online correction were simulated in
three patients with central, peripheral, and inferior lobe
tumor locations, respectively.
Follow up
Acute toxicity was prospectively assessed for lung, eso-
phagus, and skin using the RTOG acute radiation mor-
bidity scoring criteria every week during treatment. Late
Table 2 Radiation therapy fractionations protocols
according to Abratt model.
Targets
numbers
Dose (Gy)
infraction
Number of
fractions
BED
(Gy)
18 12 4 106
5 8 7 101
38 5 7 2
3 6 10 96
36 8 7 7
* BED: biological effective dose.
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tem considering only the lung symptoms (Common
Toxicity Criteria version 2). Our follow up lasts 16
month. The patients got recheck for chest CT every 3
months. The tumor response was evaluated by a senior
radiologist and a radiation oncologist using the RECIST
criteria.
Statistical analysis
F-test was applied for error analysis using SPSS software
package.
Results
A total of 347 CBCT including 150 pre-correction, 130
post-correction and 67 post-treatment scans were
acquired. The CBCT images with ABC yielded good
contrast of tumor and structures.
At free breathing, the mean (±SD) of diaphragm dis-
placement was 16.0 (±2.7) mm (range 12-24 mm). With
the use of ABC, the mean (±SD) diaphragm displace-
ment was 1.7 (±0.5) mm (range 1.0-2.5 mm). Mean
value of the breath-hold time was prolonged from 30
seconds to 57 seconds by means of training course and
inhaling oxygen in 20 patients. All patients tolerated
ABC well for CBCT scan with a duration ≥ 40 s. To
make patients more comfortable, the duration of ABC <
20 s is required during radiation delivery. All patients
were tested by the respiratory function 3 months after
treatment. The result indicated that none of these para-
meters (FEV1, FEV1/FVC) was affected by IGRT.
Interfractional errors and intrafracional errors
The pre- and post-correction positional errors for
patients using ABC in LR, SI and AP directions were
shown in Fig. 1 and Fig. 2. It shows that errors in three
directions were all decreased with online correction.
The percentage of pre-correction errors ≤ 2m mi na l l
three directions was <30%, while rose to ≥ 90% after
correction and remained 60% at the completion of treat-
ment. As shown in Table 3, the pre-correction errors in
SI direction were the largest. There was a significant
deviation of mean error in the caudal direction, with
systematic error of 5.3 mm and random error of
3.7 mm. The precorrection errors were similar in LR
and AP directions, with the systematic of 3.1 and 3.7
mm and random error of 2.1 and 2.8 mm for LR and
AP, respectively. After correction, the errors were
reduced in all three axes. The errors were similar in
three axes, with the systematic errors of 0.6 mm in LR
and 0.8 mm for both SI and AP direction; and random
errors of 0.8 mm, 1.2 mm and 1.3 mm in LR, SI and AP
direction, respectively.
After treatment, the tumor positional errors increased
compared to post-correction (Table 3). The systematic
errors were 1.2 mm for both LR and AP axes, and larger
(1.8 mm) in SI direction. The random error was larger
in AP (2.8 mm) than in LR and SI (both1.5 mm)
direction. The mean errors were all below 0.5 mm. The
post-treatment residual errors were larger than the post-
correction, with increments ≤ 1 mm, but still much smal-
ler than pre-correction errors.
PTV margin reduction and impact on normal tissue dose
In this study, with ABC device, the respiration motion
of tumor was small, only setup uncertainty was included
for margin analysis. In Table 3, the pre-correction setup
margin was largest (14.1 mm) in SI, intermediate in LR
(9.5 mm) and smallest in AP (8.2 mm) directions. The
margins decreased markedly after correction to within 3
mm in all directions. After treatment the margins
increased to 3.2 - 4.7 mm in three directions.
Table 4 shows the reductions in normal tissue dose
volume parameters using online CBCT image guidance
for each of the three GTV locations (central, peripheral,
and lower lobe). Comparisons are made between differ-
ent PTV scenarios. In patients using ABC, the reduc-
tions of 47-77.3% in lung dose volume endpoints
were achieved with CBCT correction. Reductions of
36.3-66.7% in lung dose volume endpoints were
achieved when intrafractional setup errors were
accounted for. In patients using ABC, reduction in
spinal cord doses was highest (55.2-58.5%) for central
tumor location and smaller (8.4-17%) for peripheral
locations. Comparing to precorrection (PTV1), the dose
reductions to normal tissues were greater postcorrection
(PTV2) than posttreatment (PTV3). The increment of
dose reductions in lung dose volume endpoints ranged
9.1-18.8%, and 3.3-5.9% in spinal cord maximum dose
in PTV2 compared to PTV3, suggesting increased nor-
mal tissue dose with posttreatment margin due to intra-
fractional positioning errors.
Follow up
ll patients were followed up for 6 - 16 months, with a
median of 10 months. There was one patient dying of
brain metastasis. At 6 months post-treatment, 20
(62.5%) out of 32 targets regressed completely after
treatment. 9 (28%) targets shrank more than 30% (PR).
2 (6.3%) targets had SD at 6 months post-treatment, 1
target was not assessed. An overall response rate of
90.6% (29/32) was achieved. The CR was higher in
patients with BED ≥ 100 Gy (74%) vs. BED < 100 Gy
(33%). The maximum dose of the critical organs was
well below the tolerance dose for each organ in the
whole group. The maximum value of V20 for the whole
group was 21%. The maximum point dose of spinal
cord, esophagus and mean lung were 15.7 Gy, 32 Gy
and 3.0 Gy respectively. Treatment was well tolerated.
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symptoms during and after treatment. 3 (15%) patients
had grade 1, 1 (5%) patient had grade 2 acute radiation
pulmonary toxicity. 3 (15%) had grade 1 acute esophagi-
tis. All these symptoms alleviated after treatment com-
pletion without special treatment. There was no
pulmonary or esophageal toxicity of grade 3 or above,
no acute skin toxicity and no hemotoxicity during treat-
ment. For late effects, only 2 (10%) patients had grade 1
pulmonary toxicity (imaging change but no symptom), 1
patient (5%) had grade 1 dysphasia. No other late toxici-
ties were observed.
Discussion
In this preliminary study, we evaluated the feasibility of
CBCT guided radiotherapy in combination with ABC to
restrict tumor positional error. The role of CBCT gui-
dance in improving treatment accuracy and reduction of
target margin requirements for stereotactic lung radio-
therapy using ABC procedure was studied.
At initial setup, the tumor positional error was signifi-
cant even with SBF plus ABC. Our results were similar
to literature report that utilized SBF immobilization and
portal imaging device to evaluate errors [21] which
reported the positioning errors for SBF were 2.3-4.2
mm. Negoro [22] also reported the positioning accuracy
ranged 0-8.5 mm, with the mean of 3.2 mm. Our results
demonstrated that the initial errors with SBF plus ABC
immobilization were greater than those reported
recently which also utilized CBCT online guidance and
4D-CT to detect errors in lung tumor immobilized with
SBF alone. In their study, the systematic error ranged
Figure 1 The tumor positional errors pre- and post-correction, and post-treatment in three dimensions. The abscissa represents the
number of CBCT acquired, and the ordinate represents the errors (in mm), a: LR, b: SI, c: AP.
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[16]. This may be partly due to the poor long-term
reproducibility of tumor position when repeat CT scans
were performed during ABC [23]. It should be men-
tioned that the value of using the SBF for improving
setup accuracy in SBRT is controversial. In a recent
study reported by Sonke et al [20], 65 patients with
small peripheral lung tumors treated with SBRT without
a SBF. In their study the positioning accuracy was
evaluated using 4DCT and CBCT imaging, and their
results were similar to ours. Although online correction
markedly reduced the positional error, the tumor posi-
tion varied during treatment and might affect the dose
distribution in stereotactic radiotherapy. The post-treat-
ment residual systematic errors increased, with the
greatest increment of 1 mm in SI direction, and 0.4 mm
for both LR and AP direction. The increment of intra-
fractional random error was 1.5 mm in AP, 0.3 mm in
Figure 2 The ovelapping of targets between simulation CT and CBCT scans of a right upper lung NSCLC. The pink circle represents the
GTV and green circle represents the PTV contours in planning CT. From left to right: transverse, sagital and coronal. A: precorrection, shows
shifts of the target position from planning contours. B: Post-correction with online correction, shows satisfactory overlapping of the contours
between simulation and CBCT images. C: Post-treatment, the targets in CBCT still overlaps well with the contours in planning CT.
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reported on intrafractional tumor position variation,
especially in patients applying ABC. Uematsu et al. [24]
used CT scan to measure the intrafraction lung tumor
position error and observed that the intrafraction posi-
tional variation was small. Guckenberger et al. [25] has
utilized CBCT to determine intrafractional error and
postulated that 90% of the intrafractional position errors
were within 4.8 mm. A recent literature [18] reported
that the mean (SD) intrafractional errors of -0.1 mm
(1.1 mm), 0.2 mm (1.4 mm) and -0.1 mm (1.5 mm) in
LR, SI and AP axes respectively, for thoracic tumors at
free breathing, which were smaller than this cohort of
patients. This implies that using of ABC might increase
the intrafractional patient motion. This might be due to
the using of ABC which introduces more procedures
and variations [16].
Based on our study, the use of ABC has reduced
respiration motion. With ABC, the average diaphragm
displacement was significantly reduced from 16.0 mm to
1.7 mm. Hanley et al. [26] has reported that the dia-
phragm motion was reduced from 26.4 mm to 2.5 mm
(0.5-4.9 mm) with ABC procedure. Sarrut [27] reported
the lung tumor motion of 0.9-5.9 mm with the use of
ABC. Our study also showed high reproducibility of 2
ABC procedures, with a diaphragm movement error of
3 mm. However, there is limitation of using diaphragm
position as a surrogate for tumor. This is because that
the diaphragm is susceptible to imaging artifacts due to
large and rapid motion, and the diaphragm motion may
also be influenced by nonrespiratory activity [28].
As ABC was applied to all patients in this study, the
tumor respiration motion was small (< 3 mm), the inter-
nal target volume (ITV) was considered roughly equal to
CTV. Compared to the reliability of tumor motion (aver-
age displacement being 1.4 ± 1.0 mm) measured by 4D
CT [29], the reliability of tumor motion measured by
fluoroscopy is similar. For simplification, the PTV margin
calculation only considered setup errors, other error
sources such as delineation uncertainty and breathing
pattern variation were not accounted for in this study.
The pre-correction PTV margin was 9.5 mm in LR, 14.1
mm in SI and 8.2 mm in AP direction. However, it was
recommended a uniform PTV margin of 5 mm axial and
10 mm superior-inferior be added for stereotactic lung
radiotherapy when image guidance is not used [16]. Our
results showed that the margins in three axes all
exceeded the recommended margins for a magnitude
about 5 mm if CBCT guidance not applied, indicating
the necessity of image guidance for accuracy of lung
SBRT with ABC. After CBCT guided online correction,
the PTV margin was markedly reduced in all three direc-
tions. The post-correction margins ranged 1.5 to 2.1 mm
Table 3 The systematic and random errors and PTV
margins in 20 patients pre- and post-correction, and
post-treatment.
Setup error Pre-correction
(N = 150)
Post-correction
(N = 130)
Post-treatment
(N = (67)
LR SI AP LR SI AP LR SI AP
M -0.3 -1.74 -0.5 0.1 0.1 0.1 -0.4 0.3 0.4
Σ 3.7 5.3 3.1 0.6 0.8 0.8 1.2 1.8 1.2
s 2.1 3.7 2.8 0.8 1.2 1.3 1.5 1.5 2.8
Msetup 9.5 14.1 8.2 1.5 2.1 2.1 3.2 4.7 3.5
Abbreviations: N = number of CBCT scans; M = group mean error; Σ =S Do f
individual means for setup error; s = root-mean-square of individual SD for
setup error; LR = left-to-right; SI = superior-inferior; AP = anterior-posterior;
Msetup = PTV margin for setup. Msetup (PTV margin) = 2.5 Σ + b√s
2+s
2
p - bsp
Table 4 Reductions in normal tissue dose volume parameters using online CBCT image guidance and ABC for SBRT of
three GTV (16 cc) location
Normal tissue parameter Dose absolute reduction value Dose reduction %
PTV1 PTV2 PTV3 from PTV1
to PTV2
from PTV1
to PTV3
from PTV2 to PTV3
Mean lung dose(Gy)
central location 5.42 2.42 2.91 55.4 46.3 9.1
peripheral location 5.05 2.47 3.22 51.1 36.3 14.8
inferior lobe of lung 11.46 6.07 7.47 47.0 34.8 12.2
Lung V20 (%)
central location 11 2.5 3.7 77.3 66.7 10.6
peripheral location 8 2.5 4 68.8 50.0 18.8
inferior lobe of lung 21 10 12 52.4 42.9 9.5
Spinal cord Maximum dose(Gy)
central location 59.34 24.64 26.58 58.5 55.2 3.3
peripheral location 6.91 5.99 6.32 13.3 8.4 4.9
inferior lobe of lung 22.50 18.67 20.00 17.0 11.1 5.9
Abbreviations: PTV1 = precorrection margins with ABC; PTV2 = postcorrection margins with ABC; PTV3 = posttreatment residual margin with ABC+CBCT-
correction; V20 = volume of both lungs receiving ≥ 20 Gy.
Shen et al. Radiation Oncology 2010, 5:19
http://www.ro-journal.com/content/5/1/19
Page 7 of 9which were similar to the literature which utilized CBCT
online correction for lung patients [16]. The PTV mar-
gins at the completion of treatment were increased as
compared to the post-correction margins. The post-treat-
ment margins were 3.2-4.7 mm in three directions. It was
suggested by some investigators that at least 5 mm mar-
gin should be added for individualized PTV if image
guidance and SBF is used [30]. When intra-and interfrac-
tional errors were both accounted for, the PTV margin
reduction with online correction ranged about 5 to 10
mm in different axes. In our study the online correction
resulted in reduction of lung dose volume endpoints of
47-77.3%, and 55.2-58.5% in spinal cord doses for
patients using ABC at different tumor locations. It could
be inferred from our study that CBCT and online correc-
tion can significantly reduce normal tissue doses. As in
our study the tumor respiration motion was not evalu-
ated, the benefit of ABC on ITV reduction could not be
discussed. It has been indicated that most lung tumors
do not exhibit significant motion [31] and there remains
inter- breath hold variability in peripheral lung tumor
position with the use of ABC inspiration breath hold,
which prevents significant PTV margin reduction. How-
ever, lung volumes can significantly increase, thereby
decreasing the mass of lung within a standard PTV [32].
In addition, ABC may result in a mean relative reduction
in lung DVH parameters determining risk of pneumonitis
by up to 25% with the potential for safe dose escalation as
reported in other study [33]. 4DCT scan has become
more popular for SBRT, it has been reported that using
mid-ventilation CT scans for treatment planning instead
of the conventional free-breathing CT scans, margin
reduction is possible, which can reduce the treatment
volume up to 50% [34].
Our study found that hypofractionated radiotherapy
with BED ranged 72 to 100 Gy could achieve high CR
(62.5%), The hypofractionated radiotherapy has radio-
biological advantages of counteracting tumor accelerated
proliferation. Quite a few researches have been pub-
lished which showed high local tumor control and sur-
prisingly low toxicities with BED of 100 Gy [35-39]. The
response rate in our study seems higher than that
reported for NSCLC SBRT, which were assumed to be
partly due to the heterogeneity of histopathology in this
cohort, since half the cases were metastatic tumors from
head and neck, esophagus or breast which were radiore-
sponsive. The small tumor size and small number of
cases included in this cohort might be the other contri-
buting factors.
The patients tolerated the treatment well. Only grade
1-2 acute toxicity occurred in 35% of the patients and
15% had grade I late toxicity. Though immobilization
device combined with ABC could effectively reduce
respiration motion of target, the total margin was not
reduced. With the use of online CBCT guided setup
correction, PTV margin was substantially reduced,
which explained the low toxicity in this patient cohort.
Similar results were reported by Fukumoto et al [40]
who treated 22 stage I patients with image guided hypo-
fractionated radiotherapy (48-60 Gy in 8 fractions) and
found nearly no impairment of pulmonary functions.
In conclusion, for lung cancer hypofractionated radio-
therapy using ABC, CBCT guided online correction
effectively reduced setup errors and PTV margins.
CBCT guidance markedly improved the precision of
lung SBRT which might offer a potential dose escalation
and effective reduction of normal tissue toxicity.
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